Valuation: Erasca, Inc.

Market Cap 6.61B 5.78B 5.33B 4.9B 9.29B 636B 9.45B 63.66B 24.98B 311B 24.83B 24.28B 1,072B P/E 2026 *
-22.2x
P/E 2027 * -37.8x
Enterprise Value 6.13B 5.36B 4.95B 4.55B 8.61B 590B 8.76B 59.04B 23.16B 288B 23.03B 22.52B 994B EV / Sales 2026 *
-
EV / Sales 2027 * 11,991x
Free-Float
89.34%
Yield 2026 *
-
Yield 2027 * -
1 day+9.03%
1 week+12.67%
Current month+16.05%
1 month+47.33%
3 months+16.81%
6 months+122.38%
Current year+471.51%
1 week 17.63
Extreme 17.632
21.6
1 month 13.42
Extreme 13.42
21.6
Current year 3.36
Extreme 3.36
24.28
1 year 1.33
Extreme 1.3301
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.47
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2019
Director of Finance/CFO 43 07/01/2021
Chief Tech/Sci/R&D Officer - 25/05/2022
Director TitleAgeSince
Chairman 54 01/10/2018
Director/Board Member 79 01/06/2018
Director/Board Member 58 02/07/2018
Date Insider Type Main position Quantity % Market Cap.
06-26Free

Director

29,888 0.0096%
06-26Free

Director

29,888 0.0096%
06-26Free

Director

29,888 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
+9.03%+12.67%+1,407.80%+708.37% 6.06B
-0.17%+1.47%+3.16%+6.80% 50.35B
-0.29%-2.81%+387.81%+591.82% 39.32B
-0.49%+1.48%+31.16%-6.46% 34.69B
+1.53%+3.11%+15.41%+58.54% 34.08B
+1.68%-0.62%+3.30%+27.34% 26.63B
+1.13%-3.11% - - 16.49B
-1.29%-0.52%+69.24%+117.60% 15.31B
+0.43%+3.34%+14.96%+17.46% 13.8B
+2.45%+3.99%+18.20%-30.12% 12.87B
Average +1.40%+1.45%+216.78%+165.70% 24.96B
Weighted average by Cap. +0.61%+0.92%+116.43%+137.55%

Financials

2026 *2027 *
Net sales - 500K 437K 403K 371K 702K 48.11M 714K 4.81M 1.89M 23.52M 1.88M 1.84M 81.05M
Net income -299M -261M -241M -221M -419M -28.73B -427M -2.87B -1.13B -14.04B -1.12B -1.1B -48.4B -189M -166M -153M -140M -266M -18.22B -271M -1.82B -715M -8.91B -711M -696M -30.69B
Net Debt -480M -420M -387M -356M -674M -46.18B -686M -4.62B -1.81B -22.57B -1.8B -1.76B -77.81B -616M -539M -497M -457M -865M -59.28B -880M -5.93B -2.33B -28.98B -2.31B -2.26B -99.87B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
15/07/26 $21.26 +9.03% 9,042,476
14/07/26 $19.50 +8.94% 10,704,537
13/07/26 $17.90 -3.40% 2,555,112
10/07/26 $18.53 -3.39% 3,018,656
09/07/26 $19.18 +1.64% 4,199,946
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.26USD
Average target price
21.90USD
Spread / Average Target
+3.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock